Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2026 06:18 ET | Source: Italfarmaco

Italfarmaco Announces Managed Entry Agreement in Georgia for Givinostat as Treatment for Patients with Duchenne Muscular Dystrophy

MILAN, Italy, July 31, 2026 – Italfarmaco S.p.A. today announced a managed entry agreement with the Georgian Ministry of Health for givinostat (Duvyzat®) as a treatment for patients with Duchenne...
July 30, 2026 06:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Agios announces second quarter 2026 financial results and provides business update.
July 29, 2026 09:00 ET | Source: Citizen Health

Angelman Syndrome Foundation and Citizen Health Partner to Put Advanced AI to Work for Every Angelman Family

Angelman Foundation partners with Citizen Health
July 24, 2026 08:53 ET | Source: Neuraxpharm; Minoryx Therapeutics

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease.
July 23, 2026 07:00 ET | Source: NMD Pharma

NMD Pharma Announces Publication Identifying Neuromuscular Junction Transmission Failure as a Novel Contributor to Age-Related Muscle Weakness

New publication identifies neuromuscular junction transmission failure as a novel mechanism contributing to sarcopenia, with preclinical studies showing that ClC-1 inhibition improves neuromuscular...
July 23, 2026 01:00 ET | Source: NMD Pharma

NMD Pharma Announces Publication Identifying Neuromuscular Junction Transmission Failure as a Novel Contributor to Age-Related Muscle Weakness

New publication identifies neuromuscular junction transmission failure as a novel mechanism contributing to sarcopenia, with preclinical studies showing that ClC-1 inhibition improves neuromuscular...
July 21, 2026 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Agios provides update on Phase 2 trial of tebapivat in sickle cell disease
July 21, 2026 02:00 ET | Source: OMEICOS Therapeutics GmbH

OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA

OMEICOS has successfully completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA enabling a pivotal study in Primary Mitochondrial Disease (PMD).
July 20, 2026 14:06 ET | Source: American Kidney Fund

The American Kidney Fund and IgA Nephropathy Foundation Create New IgA Nephropathy Patient Guidelines (UPDATE)

ROCKVILLE, Md., July 20, 2026 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation announce the creation of a new resource for IgA nephropathy patients and...
July 20, 2026 10:18 ET | Source: American Kidney Fund

The American Kidney Fund and IgA Nephropathy Foundation Create New IgA Nephropathy Patient Guidelines

ROCKVILLE, Md., July 20, 2026 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) and the IgA Nephrology Foundation announce the creation of a new resource for IgA nephropathy patients and...